User profiles for Kiran Patel

Kiran Patel

Janssen
Verified email at its.jnj.com
Cited by 30104

[HTML][HTML] Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

…, A Allred, D Ouellet, KB Kim, K Patel… - … England Journal of …, 2012 - Mass Medical Soc
Background Resistance to therapy with BRAF kinase inhibitors is associated with reactivation
of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we …

[HTML][HTML] Improved survival with MEK inhibition in BRAF-mutated melanoma

…, FS Wu, D Ouellet, AM Martin, K Patel… - … England Journal of …, 2012 - Mass Medical Soc
Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found
in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves …

[HTML][HTML] Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

…, D Ouellet, AM Martin, N Le, K Patel… - … England Journal of …, 2014 - Mass Medical Soc
Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …

[HTML][HTML] Dupilumab in adults and adolescents with eosinophilic esophagitis

…, B Beazley, E McCann, K Patel… - … England Journal of …, 2022 - Mass Medical Soc
Background Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and
interleukin-13 signaling, which have key roles in eosinophilic esophagitis. Methods We conducted …

[PDF][PDF] Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with …

…, C Garbe, S O'Day, A Daud, JM White, C Xia, K Patel… - 2007 - academia.edu
Purpose This phase III, randomized, double-blind, placebo-controlled study was conducted
to evaluate the efficacy and safety of sorafenib with carboplatin and paclitaxel (CP) in …

Mars' surface radiation environment measured with the Mars Science Laboratory's Curiosity rover

…, C Fabre, J Wray, MB Wilhelm, F Poitrasson, K Patel… - science, 2014 - science.org
The Radiation Assessment Detector (RAD) on the Mars Science Laboratory’s Curiosity rover
began making detailed measurements of the cosmic ray and energetic particle radiation …

The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular …

…, E Lee, G Heatlie, F Leyva, K Patel… - Journal of the American …, 2009 - jacc.org
Objectives : The purpose of this study was to test the hypothesis that in heart failure with
normal ejection fraction (HFNEF) exercise limitation is due to combined systolic and diastolic …

[HTML][HTML] Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF …

…, Y Xu, DJ DeMarini, NT Le, K Patel… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through
activation of MEK. The purpose of this study was to determine the response rate (RR) for …

Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries

…, A Wright, J Hsu, A Martiniuk, F Celletti, K Patel… - The Lancet, 2010 - thelancet.com
National health systems need strengthening if they are to meet the growing challenge of
chronic diseases in low-income and middle-income countries. By application of an accepted …

[HTML][HTML] Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600–mutant colorectal cancer

…, K Orford, M Motwani, Y Bai, K Patel… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
… Messersmith, Adil Daud, Razelle Kurzrock, Mariaelena Pierobon, Shonda Little, Keith
Orford, Monica Motwani, Kiran Patel, Alan P. Venook, Scott Kopetz … Messersmith, Adil …